Herbert Lepor: Influence Statistics

Herbert Lepor

Herbert Lepor

Urology, NYU Langone Health. | Department of Urology, NYU Grossman School of Medicine, New York, NY; Departments of Urology and Biochemistry and Molecular Pharmacology, NYU ...

Herbert Lepor: Expert Impact

Concepts for which Herbert Lepor has direct influence: Prostate cancer , Radical prostatectomy , Benign prostatic hyperplasia , Human prostate , Smooth muscle , Radical retropubic prostatectomy , Prostatic hyperplasia .

Herbert Lepor: KOL impact

Concepts related to the work of other authors for which for which Herbert Lepor has influence: Prostate cancer , Benign prostatic hyperplasia , Erectile dysfunction , Urinary tract , Active surveillance , Sexual function , Magnetic resonance .

KOL Resume for Herbert Lepor

Year
2021

Urology, NYU Langone Health.

Perlmutter Cancer Center, New York University, New York, New York

NYU Langone Medical Center, Manhattan, NY

2020

Department of Urology, NYU Langone Health, New York, NY

2019

Department of Urology, NYU Langone Health New York, NY.

New York University School of Medicine

2018

Department of Urology, New York University School of Medicine, New York, New York. Electronic address:

New York, NY

2017

Department of Urology, New York University School of Medicine, New York, NY

New York University, New York, New York

2016

Department of Radiology, Center for Biomedical Imaging, and, Department of Urology, Division of Urologic Oncology, NYU School of Medicine, NYU Langone Medical Center, New York, N.Y., USA

New York University Cancer Institute

2015

Division of Urologic Oncology, NYU School of Medicine, NYU Langone Medical Center Department of Urology New York New York USA

NYU Langone Medical Center, New York, NY.

Department of Urology, Smilow Comprehensive Prostate Cancer Center, New York University School of Medicine, New York, New York

2014

Department of Urology New York, NY.

NYU Langone Medical Center, NY, USA

2013

Department of Urology, New York Univeristy Langone Medical Center, New York, NY

New York University Cancer Institute, New York, New York

2012

Department of Urology, New York University School of Medicine, New York and Department of Epidemiology and Population Health, Albert Einstein College of Medicine (IA), Bronx, New York

Chief, Division of Surgical Innovation, Technology and Translation, Principal Investigator, Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Medical Center; Professor of Urology and Pediatrics, The George Washington University, Washington, DC

Professor and Director of Urology, Johns Hopkins School of Medicine, Baltimore, Maryland

2011

Department of Urology, NYU Medical Center

New York University Cancer Institute (M.E.M., H.L., P.L.), New York University School of Medicine

2010

Department of Urology, New York University, New York, New York USA

New York University School of Medicine, New York, NY

2009

Department of Urology, School of Medicine, New York University, NY, USA

2008

Department of Urology, NYU School of Medicine, New York, New York

Prominent publications by Herbert Lepor

KOL-Index: 21557 . PURPOSE: Optimization of prostate biopsy requires addressing the shortcomings of standard systematic transrectal ultrasound guided biopsy, including false-negative rates, incorrect risk stratification, detection of clinically insignificant disease and the need for repeat biopsy. Magnetic resonance imaging is an evolving noninvasive imaging modality that increases the accurate localization ...
Known for Magnetic Resonance | Prostate Biopsy | Cancer Detection | Imaging Guided
KOL-Index: 17877 . BACKGROUND: Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown. METHODS: We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of ...
Known for Combination Therapy | Clinical Progression | Benign Prostatic Hyperplasia | Placebo Doxazosin
KOL-Index: 17019 . BACKGROUND: Increasing evidence supports the use of magnetic resonance imaging (MRI)-ultrasound fusion-targeted prostate biopsy (MRF-TB) to improve the detection of clinically significant prostate cancer (PCa) while limiting detection of indolent disease compared to systematic 12-core biopsy (SB). OBJECTIVE: To compare MRF-TB and SB results and investigate the relationship between biopsy ...
Known for Prostate Biopsy | Resonance Imaging | Multiparametric Magnetic | 6 Pca
KOL-Index: 16910 . OBJECTIVES: Transurethral resection of the prostate (TURP) represents the accepted standard of surgical therapy for the management of symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH). However, this is a major operative procedure associated with significant perioperative morbidity. Visual laser ablation of the prostate (VLAP) utilizing a ...
Known for Transurethral Resection | Prostatic Hyperplasia | Patients Vlap | Prostate Turp
KOL-Index: 16874 . PURPOSE: We determine whether site specific labeling of sextant prostate biopsy cores predicts the site of extracapsular extension in a radical prostatectomy specimen, thereby justifying increased cost of pathological evaluation. MATERIALS AND METHODS: Between January 1994 and December 1997, 407 radical prostatectomies were performed at our institution by a single surgeon (H. L.). Surgical ...
Known for Extracapsular Extension | Biopsy Core | Surgical Specimen | Positive Predictive
KOL-Index: 15758 . Complexed PSA (cPSA) has been shown to improve specificity in the detection of prostate cancer over that of total PSA (tPSA) testing in men with tPSA values greater than the cutoff value of 4.0 ng/mL. However, recent studies have reported a 25% incidence of prostate cancer in men with tPSA values in the 2.5- to 4.0-ng/mL range. We performed a multicenter study of cPSA in a population of ...
Known for Prostate Cancer | Early Detection | Specific Antigen | Tpsa Values
KOL-Index: 15396 . PURPOSE: While magnetic resonance imaging-ultrasound fusion targeted biopsy allows for improved detection of clinically significant prostate cancer, a concerning amount of clinically significant disease is still missed. We hypothesized that a number of these misses are due to the learning curve associated with magnetic resonance imaging-ultrasound fusion targeted biopsy. We report the ...
Known for Prostate Biopsy | Resonance Imaging | Learning Curve | Cancer Detection
KOL-Index: 15313 . PURPOSE: We investigated the role of performing 2 consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate in a single office visit as the protocol for detecting prostate cancer in men presenting for the first time with an abnormal digital rectal examination and/or elevated serum prostate specific antigen (PSA). MATERIALS AND METHODS: A total of 137 consecutive ...
Known for Biopsies Prostate | Consecutive Sets | Ultrasound Guided | Serum Psa
KOL-Index: 14591 . PURPOSE: Repeat biopsy has been advocated following the diagnosis of high grade prostatic intraepithelial neoplasia to exclude coexisting prostate cancer. We further define the natural history of high grade prostatic intraepithelial neoplasia by determining the incidence of prostate cancer 3 years following diagnosis. MATERIALS AND METHODS: A total of 31 men underwent followup interval ...
Known for Prostate Cancer | Prostatic Intraepithelial | Specific Antigen | Biopsy 3
KOL-Index: 14452 . OBJECTIVES: To determine the feasibility and desirability of removing the urinary catheter 7 days after radical retropubic prostatectomy. METHODS: Between February 28, 2000 and October 5, 2000, 184 men underwent radical retropubic prostatectomy by a single surgeon. Of these men, 97% underwent gravity cystography under fluoroscopic control on postoperative day (POD) 7. The indwelling ...
Known for Urinary Catheter | Radical Retropubic Prostatectomy | Early Removal | 3 Months
KOL-Index: 14268 . PURPOSE: We determine the effect of placebo, finasteride, terazosin and a combination of drugs on bother due to symptoms, quality of life and patient perception of improvement, and identify baseline clinical factors that predict clinical response to medical therapy. MATERIALS AND METHODS: A total of 1,229 subjects with clinical benign prostatic hyperplasia (BPH) were randomized to 1 year ...
Known for Medical Therapy | Quality Life | Finasteride Terazosin | Clinical Bph
KOL-Index: 14095 . OBJECTIVES: To determine the feasibility and safety of removing the urinary catheter on postoperative day (POD) 3 or 4 after radical retropubic prostatectomy (RRP). METHODS: Between January 2001 and August 2001, gravity cystography was performed on POD 3 or 4 after RRP by a single surgeon (H.L.) on 151 men. The urinary catheter was removed on POD 3 or 4 providing no extravasation was ...
Known for Urinary Catheter | Postoperative Day | 3 Months | Retropubic Prostatectomy
KOL-Index: 13452 . A symptom index for benign prostatic hyperplasia (BPH) was recently developed and validated by the Multidisciplinary Measurements Committee of the American Urologic Association, Inc. (AUA). The AUA symptom index ascertains the severity of seven nonspecific urinary symptoms associated with clinical BPH. The objective of the present study was to determine the influence of aging and gender on ...
Known for Aua Symptom | Aged Female Humans | Prostatic Hyperplasia | Surveys Questionnaires
KOL-Index: 13342 . The clinical manifestations of benign prostatic hyperplasia (BPH) are related primarily to bladder outlet obstruction resulting from enlargement of the prostate gland. Transurethral prostatectomy is the most common treatment currently offered for BPH in the United States. The primary objective of the present randomized placebo controlled multicenter study was to determine the efficacy and ...
Known for Terazosin Treatment | Efficacy Safety | Benign Prostatic Hyperplasia | Symptomatic Bph

Key People For Prostate Cancer

Top KOLs in the world
#1
Ahmedin M Jemal
united states breast cancer addis ababa
#2
Peter T Scardino
prostate cancer active surveillance erectile function
#3
Rebecca L Siegel
united states colorectal cancer incidence rates
#4
Johnathan I Jonathan
prostate cancer gleason score needle biopsy
#5
Philip W Kantoff
prostate cancer psma adc androgen deprivation therapy
#6
PATRICK CRAIG Walsh
prostate cancer specific antigen pathological stage

Urology, NYU Langone Health. | Department of Urology, NYU Grossman School of Medicine, New York, NY; Departments of Urology and Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY. Electronic address: Herbert.Lepor@